海创药业：关于首次公开发行股票部分募投项目子项目调整的公告

Core Viewpoint - Haichuang Pharmaceutical announced adjustments to certain sub-projects within its "Innovative Drug R&D Project" to enhance the efficiency of fundraising, while keeping the total investment amount unchanged [2]. Group 1 - The company will hold its second board meeting and the tenth supervisory board meeting on August 13, 2025, to review the proposal for adjustments [2]. - The adjustments to the fundraising projects require approval from the company's shareholders' meeting [2].